N-Substituted-3-alkoxy-derivatives of dextromethorphan are functional NMDA receptor antagonists in vivo: Evidence from an NMDA-induced seizure model in rats

[1]  M. Hall,et al.  The Opioid Crisis and the Future of Addiction and Pain Therapeutics , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[2]  S. Bergese,et al.  A comprehensive literature review , 2019 .

[3]  T. Gould,et al.  Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms , 2018, Pharmacological Reviews.

[4]  J. Witkin,et al.  Rapid-Acting Antidepressants. , 2018, Current pharmaceutical design.

[5]  Joshua B. Ewen,et al.  Randomized open-label trial of dextromethorphan in Rett syndrome , 2017, Neurology.

[6]  R. Matsumoto,et al.  Deuterated (d6)-dextromethorphan elicits antidepressant-like effects in mice , 2017, Pharmacology Biochemistry and Behavior.

[7]  M. Ghasemi,et al.  Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders , 2017, Neuroscience & Biobehavioral Reviews.

[8]  B. Lucke-Wold,et al.  Behavioral and biochemical effects of ketamine and dextromethorphan relative to its antidepressant-like effects in Swiss Webster mice , 2016, Neuroreport.

[9]  E. Lauterbach.  Treatment Resistant Depression with Loss of Antidepressant Response: Rapid-Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule. , 2016, Psychopharmacology bulletin.

[10]  S. Traynelis,et al.  Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. , 2016, Pharmacology & therapeutics.

[11]  Kelan Thomas,et al.  Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders. , 2016, Pharmacology & therapeutics.

[12]  Jang-Han Lee,et al.  The Effects of Long-Term Ketamine Treatment on Cognitive Function in Complex Regional Pain Syndrome: A Preliminary Study. , 2016, Pain medicine.

[13]  R. Matsumoto,et al.  Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice , 2015, Behavioural Brain Research.

[14]  Pierre N Tariot,et al.  Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. , 2015, JAMA.

[15]  Allison C. Nugent,et al.  Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review , 2015, Therapeutic advances in chronic disease.

[16]  K. Chen,et al.  A Placebo-Controlled Trial of Dextromethorphan as an Adjunct in Opioid-Dependent Patients Undergoing Methadone Maintenance Treatment , 2015, The international journal of neuropsychopharmacology.

[17]  Daniel Z Lieberman,et al.  The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS. , 2014, Journal of affective disorders.

[18]  R. Matsumoto,et al.  Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan , 2014, PloS one.

[19]  S. Amiri,et al.  The Therapeutic Effect of Adding Dextromethorphan to Clonidine for Reducing Symptoms of Opioid Withdrawal: A Randomized Clinical Trial , 2013, ISRN psychiatry.

[20]  Wang-Tso Lee,et al.  Dextromethorphan in the treatment of early myoclonic encephalopathy evolving into migrating partial seizures in infancy. , 2012, Journal of the Formosan Medical Association = Taiwan yi zhi.

[21]  S. Schachter,et al.  The NMDA receptor complex as a therapeutic target in epilepsy: a review , 2011, Epilepsy & Behavior.

[22]  J. Witkin.  Commentary [the mood in the field of antidepressant drug discovery]. , 2011, CNS & neurological disorders drug targets.

[23]  Jeffrey Cummings,et al.  Dextromethorphan Plus Ultra Low‐Dose Quinidine Reduces Pseudobulbar Affect , 2010, Annals of neurology.

[24]  P. Skolnick,et al.  Glutamate-based antidepressants: 20 years on. , 2009, Trends in pharmacological sciences.

[25]  Suneil K. Kalia,et al.  NMDA receptors in clinical neurology: excitatory times ahead , 2008, The Lancet Neurology.

[26]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[27]  F. Tortella,et al.  Attenuation of the stimulant and convulsant effects of cocaine by 17-substituted-3-hydroxy and 3-alkoxy derivatives of dextromethorphan , 2003, Pharmacology Biochemistry and Behavior.

[28]  D. Hewitt.  The Use of NMDA‐Receptor Antagonists in the Treatment of Chronic Pain , 2000, The Clinical journal of pain.

[29]  John H Krystal,et al.  Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.

[30]  V. Mirtsou-Fidani,et al.  A phase I clinical trial of dextromethorphan in intractable partial epilepsy. , 1999, Methods and findings in experimental and clinical pharmacology.

[31]  J. Witkin,et al.  Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice , 1999, Psychopharmacology.

[32]  W. Danysz,et al.  Low-affinity NMDA receptor channel blockers inhibit acquisition of intravenous morphine self-administration in naive mice. , 1999, European journal of pharmacology.

[33]  C. Parsons,et al.  Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data , 1999, Neuropharmacology.

[34]  F. Tortella,et al.  Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced by cocaine. , 1999, The Journal of pharmacology and experimental therapeutics.

[35]  C. Parsons,et al.  Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization , 1999, Neuropharmacology.

[36]  P. Popik,et al.  Opiate withdrawal with dextromethorphan. , 1997, The American journal of psychiatry.

[37]  F. Vocci,et al.  The Effects of NMDA Receptor Antagonists and Nitric Oxide Synthase Inhibitors on Opioid Tolerance and Withdrawal , 1995, Neuropsychopharmacology.

[38]  J. Witkin,et al.  Sensitive and rapid behavioral differentiation ofN-methyl-d-aspartate receptor antagonists , 1994, Psychopharmacology.

[39]  F. Tortella,et al.  Novel anticonvulsant analogs of dextromethorphan: improved efficacy, potency, duration and side-effect profile. , 1994, The Journal of pharmacology and experimental therapeutics.

[40]  F. Tortella,et al.  Synthesis and evaluation of 3-substituted 17-methylmorphinan analogs as potential anticonvulsant agents. , 1992, Journal of medicinal chemistry.

[41]  J. Leander,et al.  The behavioral pharmacology of NMDA receptor antagonists. , 1990, Trends in pharmacological sciences.

[42]  P. Skolnick,et al.  Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. , 1990, European journal of pharmacology.

[43]  J. Bormann,et al.  Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. , 1989, European journal of pharmacology.

[44]  M. Pontecorvo,et al.  Dextromethorphan inhibits NMDA-induced convulsions. , 1988, European journal of pharmacology.

[45]  P. Ornstein,et al.  N-Methyl-d-aspartic acid-induced lethality in mice: selective antagonism by phencylidine-like drugs , 1988, Brain Research.

[46]  F. Wilcoxon,et al.  A simplified method of evaluating dose-effect experiments. , 1948, The Journal of pharmacology and experimental therapeutics.

[47]  P. Reddy,et al.  Role of Glutamate and NMDA Receptors in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.

[48]  M. Chamanara,et al.  The role of NMDA receptor and nitric oxide/cyclic guanosine monophosphate pathway in the antidepressant-like effect of dextromethorphan in mice forced swimming test and tail suspension test. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[49]  T. Reisine.  Opioid analgesics and antagonists , 1996 .

[50]  H. Wieser,et al.  Improvement of medically refractory temporal lobe epilepsy with dextromethorphan , 1992 .

[51]  F. Tortella,et al.  Modulators of N-methyl-D-aspartate protect against diazepam- or phenobarbital-resistant cocaine convulsions. , 1991, Life sciences.